Trials / Recruiting
RecruitingNCT07304518
Phase II Trial of PRT-064040 Nasal Spray for the Treatment of Migraine in Adults
Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase II Trial of PRT-064040 Nasal Spray for the Acute Treatment of Migraine
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 456 (estimated)
- Sponsor
- Sichuan Purity Pharmaceutical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to learn about the efficacy and safety of PRT-064040 Nasal Spray versus placebo in the acute treatment of moderate or severe migraine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PRT-064040 nasal spray | A single dose of PRT-064040 nasal spray |
| DRUG | Placebo | A single dose of placebo matched to PRT-064040 nasal spray |
Timeline
- Start date
- 2026-01-26
- Primary completion
- 2026-09-01
- Completion
- 2026-10-01
- First posted
- 2025-12-26
- Last updated
- 2026-01-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07304518. Inclusion in this directory is not an endorsement.